•
China-based Alibaba Health Information Technology Ltd (HKG: 0241) has released its financial report for the first half of 2022 (ended September 30, 2022), recording total revenues of RMB 11.5 billion (USD 1.6 billion), representing a 22.9% year-on-year (YOY) increase. Business PerformanceAliHealth’s self-operated pharmaceutical direct sales business generated RMB 10.01 billion…
•
China-based 3D Medicines Inc. (HKG: 1244) is set to make an initial public offering (IPO) of 16.35 million shares on the Hong Kong Stock Exchange. The share price is expected to range from HKD 22.96 to 26.24 (USD 2.94 to USD 3.36) per share, with a maximum gross take-home of…
•
The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) has released its summary of China’s trading situation in the health sphere during the first three quarters of 2022. According to Chinese government customs statistics, China recorded a medical product trade surplus in the period,…
•
China-based Nuance Pharma has announced a partnership with DKSH Hong Kong Business Unit Healthcare to launch Bentrio nasal spray in Hong Kong and Macau. Under the agreement, DKSH HK will provide full-agency services, including key account management, marketing promotions, supply chain, and distribution for Bentrio Nasal Spray sales operations in…
•
Shanghai-based immuno-oncology therapeutics specialist Lyvgen Biopharma has announced the initiation of an open-label, multi-center, randomized Phase II clinical study to assess the efficacy and safety of its LVGN7409 in combination with docetaxel or nivolumab for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC). The combination study is set to…
•
China-based pre-clinical Contract Research Organization (CRO) ZSHK Laboratories Limited has reportedly raised close to RMB 100 million (USD 13.89 million) in a Series B financing round. The round was led by a fund jointly initiated by AstraZeneca and CICC Capital, with participation from existing investor Ascendum Capital. The proceeds will…
•
Suzhou-based Ascentage Pharma (HKG: 6855) has announced receiving a Drug Production License (A license) following the successful on-site inspection of its global industrial plant. This marks the first such license granted in Suzhou this year, highlighting the company’s significant progress in expanding its manufacturing capabilities. Plant Profile and CapabilitiesThe GMP-…
•
China-based Everest Medicines (HKG: 1952) has announced receiving Accelerated Approval Designation (AAD) from the Taiwan Food and Drug Administration and Orphan Drug Designation (ODD) from the Ministry of Food and Drug Safety in South Korea for its lead product Nefecon (targeted-release budesonide). These designations are for the treatment of primary…
•
The 13th China (Taizhou) International Medical Expo witnessed the launch of the Taizhou-Wuxi-Lianyungang national biomedicine hub. This initiative aims to integrate the strengths of three key cities in China’s biomedicine industry, leveraging their unique advantages to drive further growth and innovation. Cities’ Profiles Hub’s PerformanceThe Taizhou-Wuxi-Lianyungang hub can boast over…
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced an equity collaboration deal with Zhejiang Dongyang Medical Materials Co., Ltd. The partnership aims to strengthen the supply of drugs and medical devices in the city of Dongyang. Financial details of the transaction were not disclosed. Transaction DetailsFollowing the deal, Dongyang…
•
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its HR20031 in patients with type 2 diabetes. This marks a significant step forward in the development of a novel treatment option for patients with poorly controlled…
•
China’s Peijia Medical Limited (HKG: 9996) has announced the first patient implant in a global first-in-man (FIM) clinical study of its MonarQ transcatheter tricuspid valve replacement (TTVR) system. This marks a significant milestone in the development of innovative treatments for tricuspid regurgitation. MonarQ TTVR System ProfileThe MonarQ TTVR system is…
•
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu Eastern New Area, focusing on medical diagnosis services, diagnostics development, and other related areas. The collaboration includes plans to establish a domestic in vitro diagnostics (IVD) manufacturing center in the region. Financial details of the…
•
Anyeep, a Suzhou-based developer of mass spectrometers, has reportedly raised close to RMB 100 million (USD 13.96 million) in a Series A financing round. The round was led by Greenriver Capital, with participation from Dunhang Investment, PEAKVEST FOF, and existing investors Frees Fund and Yuanbio Venture Capital. The proceeds will…
•
China-based Shanghai Henlius Biotech (HKG: 2696) has entered into an agreement to provide clinical study research and development (R&D) services for the COVID-19 therapy azvudine to compatriot firms HeNan Genuine Biotech Co., Ltd and Shanghai Fosun Pharmaceutical Development Co., Ltd. The services will focus on COVID-19 prevention and include clinical…
•
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving market approval from the National Medical Products Administration (NMPA) to act as the domestic agent for Definity (perflutren lipid microsphere injection). The contrast agent can now be used to enhance the recognition of the left ventricular endocardial boundary when…
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has struck a partnership with China-based CK Life Sciences to develop an AI cancer vaccine research and development (R&D) platform. The collaboration aims to leverage the respective strengths of both companies to advance the development of AI-driven cancer vaccines. Financial details of the…
•
Hangzhou-based oncology-focused clinical stage biotech Bliss Bio has announced that its clinical filing for the Category 1 therapeutic biologic product injectable BB-1709 has been accepted for review by the Center for Drug Evaluation (CDE). This marks a significant milestone in the development of BB-1709, a potential first-in-class antibody drug conjugate…
•
Xiling Lab, a Chengdu-based drug developer specializing in catalytic synthesis technology, has reportedly raised close to RMB 100 million (USD 13.96 million) in a Pre-Series B financing round. Investors included Chengdu Bio City No. 1 Equity Investment Fund, Chengdu Gaoxin New Economy Venture Capital, Pengzhou Global Biomedical Technology Achievement Transformation…
•
Shenzhen-based drug developer PrimeLink Bio has reportedly raised “hundreds of millions” of renminbi in a new financing round led by Vertex Ventures. Fosun Pharma and Kaitai Capital also participated in the round. The proceeds will be used to support technology research and development (R&D), talent recruitment, and laboratory construction. Company…